Name | Number of supported studies | Average coverage | |
|---|---|---|---|
| peripheral blood | 14 studies | 25% ± 9% | |
| lung | 11 studies | 28% ± 14% | |
| kidney | 8 studies | 19% ± 2% | |
| intestine | 7 studies | 26% ± 11% | |
| uterus | 5 studies | 24% ± 13% | |
| pancreas | 4 studies | 48% ± 16% | |
| bone marrow | 4 studies | 24% ± 7% | |
| eye | 4 studies | 31% ± 13% | |
| liver | 4 studies | 40% ± 20% | |
| lymph node | 4 studies | 22% ± 4% | |
| placenta | 3 studies | 26% ± 6% | |
| adrenal gland | 3 studies | 19% ± 1% | |
| prostate | 3 studies | 28% ± 7% | |
| skin | 3 studies | 22% ± 2% | |
| thymus | 3 studies | 41% ± 15% | |
| brain | 3 studies | 24% ± 6% | |
| breast | 3 studies | 22% ± 5% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
|---|---|---|---|---|---|---|
| esophagus | 100% | 1563.88 | 1445 / 1445 | 100% | 43.42 | 183 / 183 |
| ovary | 100% | 1787.99 | 180 / 180 | 100% | 38.27 | 430 / 430 |
| pancreas | 100% | 1065.86 | 328 / 328 | 100% | 33.73 | 178 / 178 |
| prostate | 100% | 1589.02 | 245 / 245 | 100% | 46.46 | 502 / 502 |
| stomach | 100% | 1450.41 | 359 / 359 | 100% | 54.94 | 286 / 286 |
| uterus | 100% | 1498.46 | 170 / 170 | 100% | 51.61 | 459 / 459 |
| breast | 100% | 2007.00 | 459 / 459 | 100% | 49.78 | 1117 / 1118 |
| intestine | 100% | 1685.58 | 966 / 966 | 100% | 55.25 | 526 / 527 |
| bladder | 100% | 1516.95 | 21 / 21 | 100% | 46.42 | 503 / 504 |
| liver | 100% | 1208.00 | 226 / 226 | 100% | 40.23 | 405 / 406 |
| lung | 100% | 1440.98 | 576 / 578 | 100% | 44.42 | 1155 / 1155 |
| adrenal gland | 100% | 2040.06 | 258 / 258 | 100% | 53.12 | 229 / 230 |
| kidney | 100% | 1433.87 | 89 / 89 | 100% | 30.68 | 897 / 901 |
| brain | 100% | 2010.30 | 2630 / 2642 | 100% | 35.87 | 705 / 705 |
| thymus | 100% | 1442.03 | 652 / 653 | 100% | 36.27 | 603 / 605 |
| skin | 100% | 2460.00 | 1809 / 1809 | 98% | 43.75 | 463 / 472 |
| adipose | 100% | 2030.78 | 1204 / 1204 | 0% | 0 | 0 / 0 |
| lymph node | 0% | 0 | 0 / 0 | 100% | 53.65 | 29 / 29 |
| spleen | 100% | 1782.57 | 241 / 241 | 0% | 0 | 0 / 0 |
| tonsil | 0% | 0 | 0 / 0 | 100% | 45.57 | 45 / 45 |
| ureter | 0% | 0 | 0 / 0 | 100% | 13.62 | 1 / 1 |
| muscle | 100% | 1595.07 | 802 / 803 | 0% | 0 | 0 / 0 |
| blood vessel | 100% | 1329.49 | 1330 / 1335 | 0% | 0 | 0 / 0 |
| heart | 97% | 1364.28 | 836 / 861 | 0% | 0 | 0 / 0 |
| eye | 0% | 0 | 0 / 0 | 94% | 25.65 | 75 / 80 |
| peripheral blood | 76% | 1037.05 | 708 / 929 | 0% | 0 | 0 / 0 |
| abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| GO_0032435 | Biological process | negative regulation of proteasomal ubiquitin-dependent protein catabolic process |
| GO_0006357 | Biological process | regulation of transcription by RNA polymerase II |
| GO_0051123 | Biological process | RNA polymerase II preinitiation complex assembly |
| GO_0006282 | Biological process | regulation of DNA repair |
| GO_0006974 | Biological process | DNA damage response |
| GO_0060760 | Biological process | positive regulation of response to cytokine stimulus |
| GO_0070555 | Biological process | response to interleukin-1 |
| GO_0006338 | Biological process | chromatin remodeling |
| GO_0060261 | Biological process | positive regulation of transcription initiation by RNA polymerase II |
| GO_0043066 | Biological process | negative regulation of apoptotic process |
| GO_0000492 | Biological process | box C/D snoRNP assembly |
| GO_0045893 | Biological process | positive regulation of DNA-templated transcription |
| GO_0050821 | Biological process | protein stabilization |
| GO_0006355 | Biological process | regulation of DNA-templated transcription |
| GO_1902166 | Biological process | negative regulation of intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator |
| GO_0042789 | Biological process | mRNA transcription by RNA polymerase II |
| GO_0043484 | Biological process | regulation of RNA splicing |
| GO_1902065 | Biological process | response to L-glutamate |
| GO_0045944 | Biological process | positive regulation of transcription by RNA polymerase II |
| GO_0071339 | Cellular component | MLL1 complex |
| GO_0005669 | Cellular component | transcription factor TFIID complex |
| GO_0005654 | Cellular component | nucleoplasm |
| GO_0033276 | Cellular component | transcription factor TFTC complex |
| GO_0070761 | Cellular component | pre-snoRNP complex |
| GO_0000124 | Cellular component | SAGA complex |
| GO_0005634 | Cellular component | nucleus |
| GO_0003677 | Molecular function | DNA binding |
| GO_0140297 | Molecular function | DNA-binding transcription factor binding |
| GO_0000976 | Molecular function | transcription cis-regulatory region binding |
| GO_0002039 | Molecular function | p53 binding |
| GO_0051117 | Molecular function | ATPase binding |
| GO_0046982 | Molecular function | protein heterodimerization activity |
| GO_0004402 | Molecular function | histone acetyltransferase activity |
| GO_0016251 | Molecular function | RNA polymerase II general transcription initiation factor activity |
| GO_0003713 | Molecular function | transcription coactivator activity |
| GO_0005515 | Molecular function | protein binding |
| GO_0070742 | Molecular function | C2H2 zinc finger domain binding |
| Gene name | TAF9 |
| Protein name | Transcription initiation factor TFIID subunit 9 (RNA polymerase II TBP-associated factor subunit G) (STAF31/32) (Transcription initiation factor TFIID 31 kDa subunit) (TAFII-31) (TAFII31) (Transcription initiation factor TFIID 32 kDa subunit) (TAFII-32) (TAFII32) Transcription initiation factor TFIID subunit 9 |
| Synonyms | TAF2G TAFII31 |
| Description | FUNCTION: The TFIID basal transcription factor complex plays a major role in the initiation of RNA polymerase II (Pol II)-dependent transcription . TFIID recognizes and binds promoters with or without a TATA box via its subunit TBP, a TATA-box-binding protein, and promotes assembly of the pre-initiation complex (PIC) . The TFIID complex consists of TBP and TBP-associated factors (TAFs), including TAF1, TAF2, TAF3, TAF4, TAF5, TAF6, TAF7, TAF8, TAF9, TAF10, TAF11, TAF12 and TAF13 . TAF9 is also a component of the TBP-free TAFII complex (TFTC), the PCAF histone acetylase complex and the STAGA transcription coactivator-HAT complex . TAF9 and its paralog TAF9B are involved in transcriptional activation as well as repression of distinct but overlapping sets of genes . Essential for cell viability . May have a role in gene regulation associated with apoptosis . . |
| Accessions | ENST00000509462.6 ENST00000622801.4 ENST00000512152.6 ENST00000328663.8 ENST00000616112.4 ENST00000688968.1 ENST00000617775.4 D6RHW1 ENST00000689249.1 ENST00000691076.1 ENST00000691555.1 ENST00000693414.1 ENST00000622236.4 D6RGK3 D6RIY1 ENST00000508954 ENST00000503245.6 ENST00000616867.1 ENST00000691515.1 D6RIE8 ENST00000620800.4 ENST00000504109 ENST00000508954.4 ENST00000617893.4 Q16594 ENST00000615404.1 ENST00000503245 D6RIV9 ENST00000509462 ENST00000687836.1 ENST00000506736.2 ENST00000217893.10 ENST00000690749.1 ENST00000504109.6 ENST00000512152 |